deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT03447730

Safety, Tolerability and Pharmacodynamics of SYNB1020

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1020 in Hepatic Insufficiency and Cirrhosis Patients

Sponsor: Synlogic

Conditions Cirrhosis
Interventions Placebo SYNB1020
Updated 16 times since 2018 Last updated: May 11, 2021 Started: Mar 19, 2018 Primary completion: Jul 19, 2019 Completion: Jul 19, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Interim futility analyses identified a lack of SYNB1020 efficacy.

Other terminated trials from Synlogic

More terminations from Synlogic

Other Cirrhosis trials with similar outcome

Browse all Cirrhosis trials

A PHASE1/PHASE2 clinical study on Cirrhosis, this trial is terminated or withdrawn. The trial is conducted by Synlogic and has accumulated 16 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2020 · 14 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jun 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2021 — Jun 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  2. Sep 2019 — Nov 2020 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  3. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  4. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Synlogic
Data source: Synlogic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations